The effect of stabilising agents on the organ distribution of lipid emulsions

Illum, Lisbeth; West, P.; Washington, C.; Davis, S.S.

doi:10.1016/0378-5173(89)90163-4

Cited by 43 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, more FDC than FTPA was found in the milk of sucklings after the mother rat had received Fluosol . RES uptake of such emulsions decreased with increasing droplet surface hydrophilicity. , …”

Section: Pharmacokineticsmentioning

confidence: 94%

“…RES uptake of such emulsions decreased with increasing droplet surface hydrophilicity. 1657,1658 Excretion of FTPA (administered to rats in the form of an FTPA/EYP emulsion) could be accelerated by subsequent daily intraperitoneal injections of lecithin. 1659 The t 1/2 was prolonged 3-to 4-fold, the amount of PFC temporarily retained in the liver decreased, and organ half-life reduced from ca.…”

Section: Pharmacokineticsmentioning

confidence: 99%

See 1 more Smart Citation

Oxygen Carriers (“Blood Substitutes”)Raison d'Etre, Chemistry, and Some PhysiologyBlut ist ein ganz besondrer Saft

2001

View full text Add to dashboard Cite

Pharmaceutical Corporation in San Diego; however, the opinion expressed here are solely his and not necessarily those of the Corporation. Jean G. Riess received his chemical engineer and doctorat-e `s-sciences degrees (the latter with Professor Guy Ourisson in 1963) from the University of Strasbourg. He then spent two years with John Van Wazer at Monsanto in Saint-Louis, MO, learning some phosphorus and transitionmetal chemistry. In 1968 he became Professor at the University of Nice, France, where he founded, directed, and eventually became honorary director of the Unite ´de Chimie Mole ´culaire (associated with the Centre National de la Recherche Scientifique). His research successively involved phosphorus chemistry, transition-metal chemistry, organometallics, and eventually perfluorochemicals. His present interests are in fluorocarbons, fluorinated amphiphiles, and their colloid chemistry, including fluorocarbon emulsions for in vivo O 2 delivery, fluorinated self-assemblies, and drug delivery systems. Professor Riess has published about 360 papers and holds ca. 25 patents. He has served on numerous councils and committees and has chaired or co-chaired international conferences on phosphorus chemistry and blood substitutes. He has won awards from the French Academy of Sciences, French Chemical Society, Alexander von Humboldt Stifftung, City of Nice and Controlled Release Society, as well as Alliance's first Distinguished Contribution Award. He holds an honorary Research Associate position at the University of California at San Diego and sits on the Board of Directors of Alliance Pharmaceutical Corp.

show abstract

Section: Pharmacokineticsmentioning

confidence: 94%

Section: Pharmacokineticsmentioning

confidence: 99%

Oxygen Carriers (“Blood Substitutes”)Raison d'Etre, Chemistry, and Some PhysiologyBlut ist ein ganz besondrer Saft

2001

View full text Add to dashboard Cite

show abstract

“…[449] Several other studies have confirmed that poloxamine 908 can improve the organ distribution and circulation time of intravenously injected colloidal carriers. [450][451][452][453] However, one contradictory study suggests that poloxamine-coated NPs do exhibit complement-activating nature. The authors of this study suggest instead that complement consumption is dependent upon the surface density and brush conformation of the poloxamine coating, with higher density coating correlating to suppressed complement consumption.…”

Section: Np Surface Property Modificationsmentioning

confidence: 99%

Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases

et al. 2018

View full text Add to dashboard Cite

Therapies directed toward the central nervous system remain difficult to translate into improved clinical outcomes. This is largely due to the blood-brain barrier (BBB), arguably the most tightly regulated interface in the human body, which routinely excludes most therapeutics. Advances in the engineering of nanomaterials and their application in biomedicine (i.e., nanomedicine) are enabling new strategies that have the potential to help improve our understanding and treatment of neurological diseases. Herein, the various mechanisms by which therapeutics can be delivered to the brain are examined and key challenges facing translation of this research from benchtop to bedside are highlighted. Following a contextual overview of the BBB anatomy and physiology in both healthy and diseased states, relevant therapeutic strategies for bypassing and crossing the BBB are discussed. The focus here is especially on nanomaterial-based drug delivery systems and the potential of these to overcome the biological challenges imposed by the BBB. Finally, disease-targeting strategies and clearance mechanisms are explored. The objective is to provide the diverse range of researchers active in the field (e.g., material scientists, chemists, engineers, neuroscientists, and clinicians) with an easily accessible guide to the key opportunities and challenges currently facing the nanomaterial-mediated treatment of neurological diseases.

show abstract

“…Stabilizer systems also determine the fate of nanoparticles in vivo [17,18]. As these are colloidal dispersions, stabilizers are required to reduce the interfacial tension by steric [19][20][21].…”

Section: B) Stabilizer Systemsmentioning

confidence: 99%

Innovation in Drug Carriers: Supercooled Smectic Nanoparticles

Hirlekar

Bulbule²,

Kadam³

2012

CDTH

View full text Add to dashboard Cite

Supercooled smectic nanoparticles are under investigation as potential drug carrier systems. Lipid nanoemulsions have the disadvantage of insufficient stabilization whereas solid lipid nanoparticles suffer from disadvantages like low drug incorporation tendencies. Hence there was a need to develop new drug delivery systems which could overcome these disadvantages. Liquid crystalline state also called as mesophase, has macroscopic viscosity and a less orderly state than solids but greater than that of liquids. The liquid crystalline state is classified as nematic and smectic phase. In the smectic phase the molecules are aligned side by side forming a layer and this property of the smectic phase is made use in pharmaceuticals. The various components used include lipid matrices such as cholesteryl esters and stabilizer systems. High-pressure melt homogenization and solvent evaporation are the two widely used methods for their preparation. Drugs, which can be incorporated, are mostly poorly water soluble drugs and drugs which possess very low recrystallization tendencies. In this review an attempt has been made to highlight composition, stabilizer systems, and matrix systems, method of preparation, characterization, applications and safety aspects of the supercooled smectic nanoparticles as drug carrier systems.

show abstract

The effect of stabilising agents on the organ distribution of lipid emulsions

Cited by 43 publications

References 23 publications

Oxygen Carriers (“Blood Substitutes”)Raison d'Etre, Chemistry, and Some PhysiologyBlut ist ein ganz besondrer Saft

Oxygen Carriers (“Blood Substitutes”)Raison d'Etre, Chemistry, and Some PhysiologyBlut ist ein ganz besondrer Saft

Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases

Innovation in Drug Carriers: Supercooled Smectic Nanoparticles

Contact Info

Product

Resources

About